Xilio Therapeutics, Inc. - 10-Q Filing

Xilio Therapeutics reports Q3 2026 financial results featuring ongoing collaboration with AbbVie and Gilead Sciences.

SEC EDGAR ·

Tickers: $XLO

Read the full article at SEC EDGAR

More Regulatory news